Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

LONDON, December 12, 2017 /PRNewswire/ --

ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The Global Chronic Kidney Disease (CKD) Drugs market reached $12.2bn in 2016 and is expected to grow at a CAGR of 3.9% in the first half of the forecast period. The market is dominated by calcium channel blockers and ACE inhibitors.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 171-page report you will receive 85 tables and 93 figures - all unavailable elsewhere.

The 171-page report provides clear detailed insight into the Global Chronic Kidney Disease (CKD) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Chronic Kidney Disease (CKD) Drugs market forecasts from 2018-2028

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by drug class:
- ACE inhibitors
- Angiotensin-II receptor blockers
- Calcium channel blockers
- Beta blockers: BREVIBLOC, Bystolic
- Erythropoiesis-stimulating agents (ESAs)
- Diuretics
- Others

This report provides a SWOT Analysis for each drug class.

• This report provides revenue forecast for these leading drugs:
- Aceon
- Lisinopril
- Losartan
- AVAPRO
- Twynsta
- BREVIBLOC
- Bystolic
- Mircera
- Epoetin Alfa BS
- Natrilix SR
- Spironolactone
- Urief
- AURYXIA

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by distribution channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by regional and national market:
- North America: US and Canada
- Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
- Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
- Latin America: Brazil, Mexico, Rest of Latin America
- Middle East & Africa: Saudi Arabia, South of Africa, Rest of MEA

Each regional market is further broken down by drug class and distribution channel.

• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the Global Chronic Kidney Disease (CKD) Drugs market:
- Pfizer, Inc.
- Amgen
- Roche
- GlaxoSmithKline (GSK)
- Allergan
- AbbVie
- Kissei Pharmaceutical Co., Ltd.

Buy our report today Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com (+44-(0)-20-7336-6100) or refer to our website:

https://www.visiongain.com/Report/2073/Global-Chronic-Kidney-Disease-(CKD)-Drugs-Market-Forecast-2018-2028

List of Companies Mentioned in the Report 

Abbott Laboratories

AbbVie, Inc.

Allergan plc

Amgen, Inc.

AstraZeneca Pharmaceuticals LP

Bausch & Lomb Incorporated

Baxter International Inc.

Bayer

Boehringer Ingelheim GmbH

Eisai Co., Ltd

Emory Healthcare

F. Hoffmann-La Roche Ltd

Fresenius

Galenica

GlaxoSmithKline plc

Hospira

Instituto Terapeutico Delta Ltd

Japan Chemical Research Pharmaceuticals Co., Ltd.

Keryx Biopharmaceuticals, Inc.

Kissei Pharmaceutical Co., Ltd.

Lupin Laboratories Ltd.

Manus Aktteva Biopharma LLP.

Morepen Laboratories Ltd.

Novartis International AG

ObsEva

Pfizer, Inc.

Sanofi S.A.

Sanofi-aventis U.S. LLC

Serdia Pharmaceuticals Pvt. Ltd.

Teva Pharmaceutical Industries Ltd.

Valeant Pharmaceuticals International, Inc.

Validus Pharmaceuticals, Inc.

Vifor Fresenius Medical Care Renal Pharma

Zydus Cadila

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com